16.06.2018
JSC Pharmasyntez is planning to invest in its own production of hormonal drugs in Tyumen
The declaration was made by the President of Pharmasyntez Group Vikram Punia at ACHEMA 2018 exhibition in Germany.
Nowadays, hormonal drugs in Russia take more than 90 % of the imported content. JSC Pharmasyntez with support of the Ministry of Industry and Trade of the Russian Federation and the Endocrinology Research Center of the Ministry of Health of Russian Federation is eager to change the situation in the country radically and is ready to invest €50 million in the production of modern hormonal drugs in full compliance with EU GMP standard.
GEA Belgium – the supplier of full range of production equipment for continuous batch manufacturing of drug substances in the form of tablets – was chosen by JSC Pharmasyntez as a supplier of full-cycle production lines for its plant.
‘There are plenty of critical operations in production of hormonal pharmaceuticals, including industrial safety for personnel and accurate dosing (micro-doses of hormones). GEA offered the best solutions of these issues. It is clear that reliable solutions cost a lot, but when we talk about pharmaceutical production, the quality becomes the main priority, and that’s why we choose GEA as an expert in its market share, Vikram Punia said.
The future enterprise will be up-to-date and one of the largest plants for manufacturing of hormonal drugs in Europe. JSC Pharmasyntez is planning to cooperate with world leaders in this field to promote its products in Russia and in other countries.
GEA Belgium – the supplier of full range of production equipment for continuous batch manufacturing of drug substances in the form of tablets – was chosen by JSC Pharmasyntez as a supplier of full-cycle production lines for its plant.
‘There are plenty of critical operations in production of hormonal pharmaceuticals, including industrial safety for personnel and accurate dosing (micro-doses of hormones). GEA offered the best solutions of these issues. It is clear that reliable solutions cost a lot, but when we talk about pharmaceutical production, the quality becomes the main priority, and that’s why we choose GEA as an expert in its market share, Vikram Punia said.
The future enterprise will be up-to-date and one of the largest plants for manufacturing of hormonal drugs in Europe. JSC Pharmasyntez is planning to cooperate with world leaders in this field to promote its products in Russia and in other countries.